- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05650866
Sicurezza e tollerabilità di un nuovo dispositivo impiantabile per il trattamento della disfunzione erettile
Sicurezza e tollerabilità di un nuovo dispositivo impiantabile per il trattamento della disfunzione erettile dopo prostatectomia radicale
The goal of this clinical trial is to assess if a new device is safe to use as a potential treatment for erectile dysfunction following radical prostatectomy.
The main questions it aims to answer are:
- Is the device safe?
- Does the device works well? Are the participants satisfied with the device?
Participants will be implanted with the device during the ongoing prostatectomy surgery and will be asked to complete the following tasks during 6 months follow-up:
- Come to the hospital for follow-up visits,
- Complete questionnaires,
- Activate the device every day,
- Measure erection hardness.
Researchers will compare an implanted group (participants having the device) with a control group (participants not having the device) to see if the device works well.
Panoramica dello studio
Stato
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Victoria
-
Fitzroy, Victoria, Australia, 3065
- St. Vincent's Private Hospital
-
Melbourne, Victoria, Australia, 3050
- Royal Melbourne Hospital
-
North Melbourne, Victoria, Australia, 3051
- Australian Prostate Centre
-
Richmond, Victoria, Australia, 3121
- Epworth HealthCare
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Men of ages between 30-70 years;
- Men with indication for nerve-sparing prostatectomy surgery;
- Localised prostate cancer considered suitable for bilateral nerve sparing prostatectomy according to clinical criteria
- International Index of Erectile Function (IIEF-15) erectile function domain score equal to or greater than 26 prior prostatectomy;
- Men interested in minimizing the effect of radical prostatectomy on erectile function;
- Ability to read and understand patient information materials and willingness to sign a written informed consent.
Exclusion Criteria:
- Men with neurological disease, including a history of spinal cord injury or trauma;
- IIEF-15 erectile function domain score less than 26 prior prostatectomy;
- Failure to demonstrate adequate nocturnal erectile function prior prostatectomy;
- History of erectile dysfunction, priapism and Peyronie disease;
- History of previous pelvic surgery, trauma or irradiation therapy;
- Currently have an active implantable device;
- Patient diagnosed with neurologic degenerative diseases that may negatively impact erectile functions;
- Identification of technical or clinical limitation to properly apply the use of nerve-sparing techniques during operation;
- Inability to understand and demonstrate device use instructions;
- Patients with insulin-dependent diabetes who suffer peripheral neuropathy or other diabetes associated complications;
- Patient unwillingness to engage in sexual activity;
- Patient is currently participating in another clinical investigation that would serve as a contraindication to implant a neurostimulator device to augment erectile function;
- Have participated in any drug or device trial in the last 4 weeks or plan to participate in any other drug or device study during the next 24 months;
- Possess any other characteristics that, per the investigator's judgment, may increase the risk or impair data collection for the procedure/study;
- Patient is a member of a vulnerable population (Vulnerable participants include those who lack consent capacity, including the mentally ill, prisoners, cognitively impaired participants, and employee volunteers).
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Implanted group
The study device will be implanted during the ongoing prostatectomy surgery. Participants will then be asked to activate it everyday. |
The study device is an active implantable device. The device activates the cavernous nerves by delivering electrical pulses, to trigger an on-demand erection. The daily delivery of electrical pulses to the cavernous nerves will also allow participants to recover natural erectile function. |
|
Nessun intervento: Control group
Participants in the control group will undergo standard prostatectomy and will not be implanted with the study device. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Occurrence of adverse events
Lasso di tempo: 6 months
|
Adverse events will be reported using MedDRA terminology. |
6 months
|
|
Occurrence of surgical complications
Lasso di tempo: 6 months
|
Surgical complications will be ranked according to the Clavien-Dindo classification |
6 months
|
|
Occurrence of device deficiencies
Lasso di tempo: 6 months
|
Device deficiencies will be systematically reported and recorded. |
6 months
|
|
Pain
Lasso di tempo: 6 months
|
Patients will be asked to rate pain on a visual analog scale (from 0 to 10) |
6 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Objective Device effectiveness
Lasso di tempo: 6 months
|
Erectile response obtained when activating the study device will be objectively assessed by measuring penile rigidity with the RigiScan device. |
6 months
|
|
Subjective Device effectiveness
Lasso di tempo: 6 months
|
Erectile function will be subjectively assessed by asking participants to complete validated questionnaires (International Index of Erectile Function, IIEF-15 and Erection Hardness Score, EHS). |
6 months
|
|
Erectile function recovery
Lasso di tempo: 6 months
|
Nocturnal penile erections will be assessed with the RigiScan device. Nocturnal erections reflect the extent of recovery of natural erectile function. |
6 months
|
|
Delineation of the surgical implantation procedure
Lasso di tempo: 6 months
|
The surgeon will record information related to the implantation (duration, position of the device, grading ease of implantation steps, and any comments). |
6 months
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
- CP-1.5400
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .